This study is a single-arm phase II clinical study to include 32 patients with advanced pancreatic cancer with KRAS G12D mutation to evaluate the effectiveness of HRS-4642 combined with nitutuzumab and AG for first-line treatment of advanced pancreatic cancer.
Neutrophil count≥1.5×10^9 / L;
Platelet≥100×10^9 / L;
Hemoglobin≥100 g / L;
Serum albumin≥30 g / L;
Previous treatment of targeted therapy against KRAS G12D.
Previous targeted therapy against EGFR.
Received major surgery or major trauma within 4 weeks before enrollment, or palliative local treatment (including but not limited to palliative radiotherapy, interventional therapy) within 2 weeks prior to enrollment.
Have received any other clinical study medication within 4 weeks before enrollment, except for an observational (non-interventional) clinical study or interventional clinical study follow-up.